Top Page
Venture Life
(LSE:VLG)
Venture Life (VLG) vs. iShares MSCI United Kingdom ETF (EWC)
Venture Life Business Overview & Revenue Model
Venture Life Financial Statement Overview
| Breakdown | TTM | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 51.41M | 26.59M | 51.41M | 43.98M | 32.76M | 30.08M |
| Gross Profit | 20.37M | 12.19M | 20.15M | 17.66M | 12.96M | 12.85M |
| EBITDA | 7.78M | 4.32M | 9.95M | 7.61M | 5.16M | 5.60M |
| Net Income | 742.00K | -314.00K | 921.00K | 520.00K | 2.40M | 2.37M |
Balance Sheet | ||||||
| Total Assets | 114.25M | 124.49M | 119.50M | 125.29M | 103.63M | 92.68M |
| Cash, Cash Equivalents and Short-Term Investments | 5.58M | 3.05M | 5.62M | 5.63M | 5.24M | 42.09M |
| Total Debt | 21.15M | 23.86M | 24.39M | 26.85M | 12.73M | 11.18M |
| Total Liabilities | 39.91M | 49.08M | 43.24M | 49.63M | 30.47M | 20.57M |
| Stockholders Equity | 74.33M | 75.41M | 76.25M | 75.66M | 73.16M | 72.11M |
Cash Flow | ||||||
| Free Cash Flow | 9.46M | 8.34M | 5.81M | 1.36M | -2.66M | 637.00K |
| Operating Cash Flow | 10.35M | 8.35M | 8.22M | 5.57M | 601.00K | 2.71M |
| Investing Cash Flow | -2.69M | -11.29M | -5.34M | -11.69M | -39.18M | -7.53M |
| Financing Cash Flow | -5.99M | 1.78M | -2.81M | 6.92M | 1.50M | 36.27M |
Venture Life Technical Analysis
Venture Life Peers Comparison
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
66 Neutral | £7.76B | 8.47 | 7.55% | 3.54% | 2.08% | 24.83% | |
65 Neutral | £182.13M | 33.80 | 5.04% | 1.89% | -0.17% | 592.46% | |
63 Neutral | £76.19M | 100.00 | 1.00% | ― | ― | ― | |
62 Neutral | £49.80M | 29.52 | 1.99% | ― | -10.99% | 60.65% | |
56 Neutral | £400.38M | ― | -369.20% | ― | 4.50% | 74.32% | |
50 Neutral | £130.46M | ― | ― | ― | ― |
Venture Life Corporate Events
Venture Life Group PLC, a leader in the global consumer healthcare sector, has announced the grant of share options to its directors under its 2023 Long Term Incentive Plan. This move, involving 2,500,000 ordinary shares, is aimed at aligning the interests of the company’s leadership with its long-term performance goals, as the options will vest based on specific performance criteria related to shareholder return and earnings per share. This strategic decision is expected to enhance the company’s operational focus and strengthen its market positioning.
Venture Life Group PLC has completed the sale of its contract development and manufacturing operations and select non-core products, resulting in a net cash position of approximately £36 million. The company reported a 38% increase in revenue for the first half of 2025, driven by strong contributions from the newly acquired Health & Her/Him brands. Venture Life is actively exploring M&A opportunities to enhance earnings and has made several key management appointments to support its growth strategy. The company is also changing its financial year-end to 31 May to better align with its strategic objectives.
Venture Life Group PLC announced that its Non-Executive Chairman, Paul McGreevy, has purchased 66,776 ordinary shares at a volume-weighted average price of 59.90 pence per share. This acquisition increases McGreevy’s total holdings to 963,825 shares, representing approximately 0.75% of the company’s issued share capital. This move may indicate confidence in the company’s strategic direction and could potentially impact investor perceptions positively.
Venture Life Group PLC announced that several of its directors, including the Non-Executive Chairman and the CEO, have purchased ordinary shares in the company. This move indicates a strong vote of confidence from the leadership in the company’s future prospects, potentially impacting stakeholder perceptions and market positioning positively.
Venture Life Group PLC, a leader in the global consumer healthcare sector, has announced the posting of a notice for a general meeting to shareholders, along with the release of their Annual Report for the year ending December 2024. The general meeting is scheduled for 5 August 2025 in London, following their annual general meeting held on 30 June 2025. Additionally, the company will hold an investor presentation on 3 July 2025, led by CEO Jerry Randall and CFO Daniel Wells, to discuss the final results for the year ended December 2024. This presentation is open to all existing and potential shareholders, allowing them to submit questions in advance or during the live event.
Venture Life Group PLC has announced a change in its major holdings, with BGF Investment Management Limited increasing its voting rights to 9.049%. This adjustment in holdings indicates a strategic move by BGF to strengthen its influence within the company, potentially impacting Venture Life’s strategic decisions and market positioning.
Venture Life Group PLC reported strong financial results for 2024, with an 18.9% increase in group revenue and a significant improvement in gross profit margins. The company has entered into a binding agreement to sell its contract development and manufacturing operations and certain non-core products for €62 million, which is expected to simplify its business and provide cash for growth investments. The divestment aligns with the company’s strategic focus on high-margin consumer healthcare brands, positioning it for future growth in the proactive healthy longevity market.
Venture Life Group PLC, a leader in the global consumer healthcare sector, announced that all resolutions proposed at its Annual General Meeting were passed by shareholders, except for Resolution 7 which was withdrawn. This outcome reflects strong shareholder support and may positively impact the company’s strategic direction and operations, reinforcing its position in the healthcare industry.
Venture Life Group PLC has announced the scheduling of its Annual General Meeting (AGM) for 30 June 2025, despite a delay in the release of its audited results for the year ended 31 December 2024. The delay is due to ongoing work related to the divestment of certain operations and products. As a result, the AGM will not include a resolution to receive the 2024 Annual Report and Accounts, and a separate general meeting is planned for early August to address this. This announcement highlights the company’s strategic adjustments and the impact on its reporting schedule, which may affect stakeholder engagement and decision-making timelines.
Venture Life Group PLC has announced an extension of the timeline for Mr. Jeremy Randall to exercise his share options, now set to lapse on December 31, 2025. This decision aligns with the company’s long-term strategic objectives and ensures continuity of leadership during a period of transformation and growth, reflecting the company’s commitment to maintaining stability and strategic focus.
Venture Life Group PLC announced that Mr. Paul McGreevy will remain on the Board as Chair, reversing his earlier decision to step down due to a potential conflict of interest which no longer exists. This decision means the company will not seek a replacement non-executive director, and Mark Adams will continue as a non-executive director and Chair of the Audit Committee. The CEO, Jerry Randall, expressed satisfaction with McGreevy’s continued leadership, highlighting his significant contributions to the company’s development.
Venture Life Group PLC has announced the sale of its contract development and manufacturing operations, along with certain non-core products, to BioDue S.p.A for €62 million. This strategic move allows Venture Life to streamline its operations, focus on its higher-margin core brands, and invest in growth opportunities across the UK, US, and Europe. The sale is expected to enhance the company’s financial resources, enabling further investment in its existing brands and potential acquisitions. Additionally, the transaction will transform Venture Life into a pure play consumer healthcare brand platform, emphasizing ‘Proactive Healthy Longevity’ and leveraging digital capabilities for growth.
Venture Life Group PLC has announced the sale of its contract development and manufacturing operations, along with certain non-core products, to BioDue S.p.A for €62 million. This strategic move allows Venture Life to streamline its operations, focusing on its higher-margin core brands and expanding its presence in key markets such as the UK, US, and Europe. The sale will provide significant financial resources to invest in existing brands and pursue further acquisitions, enhancing the company’s growth potential and positioning it as a pure play consumer healthcare brand platform.